| Danielle Mcclain, DNP-C | |
|
9328 E Raintree Dr, Scottsdale, AZ 85260-2098 | |
| (602) 266-8463 | |
| (602) 266-0122 |
| Full Name | Danielle Mcclain |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 9328 E Raintree Dr, Scottsdale, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902597693 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 287720 (Arizona) | Primary |
| 363L00000X | Nurse Practitioner | 287720 (Arizona) | Secondary |
| Entity Name | Endocrinology Associates P A Dtd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740294420 PECOS PAC ID: 4587555834 Enrollment ID: O20040324000719 |
News Archive
Cardinal Bank announced today that the Cardinal Bank Community Fund has awarded $5,000 to the Prevent Cancer Foundation. The mission of the Alexandria-based organization is to save lives through cancer prevention and early detection, and it has provided more than $130 million to support cancer prevention, early detection research, education, advocacy, and community outreach nationwide.
For the first time, university researchers are working side-by-side with municipal operators to advance wastewater treatment technologies and knowledge that will lead to cleaner water, a better protected ecosystem and improved public health.
Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.
Tissue engineering technologies offer new treatment strategies for the repair of peripheral nerve injury, but cell loss between seeding and adhesion to the scaffold remains inevitable.
As Congress considers reauthorizing a law that sets the fees for medical device makers, venture capitalists are emerging as a rich and influential ally of device companies eager to remove what they say are regulatory roadblocks in the approval process.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Danielle Mcclain, DNP-C 9328 E Raintree Dr, Scottsdale, AZ 85260-2098 Ph: (602) 266-8463 | Danielle Mcclain, DNP-C 9328 E Raintree Dr, Scottsdale, AZ 85260-2098 Ph: (602) 266-8463 |
News Archive
Cardinal Bank announced today that the Cardinal Bank Community Fund has awarded $5,000 to the Prevent Cancer Foundation. The mission of the Alexandria-based organization is to save lives through cancer prevention and early detection, and it has provided more than $130 million to support cancer prevention, early detection research, education, advocacy, and community outreach nationwide.
For the first time, university researchers are working side-by-side with municipal operators to advance wastewater treatment technologies and knowledge that will lead to cleaner water, a better protected ecosystem and improved public health.
Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine- (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant reduction in chorea score (p< 0.0001) as measured using the Unified Huntington's Disease Rating Scale (UHDRS) compared with baseline.
Tissue engineering technologies offer new treatment strategies for the repair of peripheral nerve injury, but cell loss between seeding and adhesion to the scaffold remains inevitable.
As Congress considers reauthorizing a law that sets the fees for medical device makers, venture capitalists are emerging as a rich and influential ally of device companies eager to remove what they say are regulatory roadblocks in the approval process.
› Verified 5 days ago
Russell S Ruzich, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Dr. Paul Joseph Schenk, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 11230 E Beck Ln, Scottsdale, AZ 85255 Phone: 480-502-9457 | |
Dr. Musab Sultan Hommos, M.B., B.S. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Soyoung Park, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 10460 N 92nd St Ste 300, Scottsdale, AZ 85258 Phone: 480-323-1573 Fax: 480-323-1375 | |
Dr. Michael Edward Killian, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: Mayo Clinic 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 085-120-6856 | |
Hesham Mubarak Ibrahim Moh Abdalla, M.B.B.S. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Kianoush Cheybani, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 9590 E Ironwood Square Dr, Ste 125, Scottsdale, AZ 85258 Phone: 480-455-3000 Fax: 866-819-6115 |